Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2023-08-25 Proxy Solicitation & In…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for PharmAbcine, detailing the agenda, date, location, and proposed changes to the articles of incorporation. It includes proxy-related information and management's explanations for the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides shareholders with the necessary information to vote on matters at a general meeting.
2023-08-25 Korean
[기재정정]주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from a Korean company (PharmAbcine) regarding an amendment to a previously announced Extraordinary General Meeting (EGM) notice. It details changes to the meeting date and the agenda items (specifically the removal of certain director and auditor appointments). Since this document is a formal notice of a meeting and its agenda, it falls under the category of Proxy Solicitation & Information Statement (PSI), as it provides shareholders with the necessary information to vote on corporate governance matters.
2023-08-25 Korean
[기재정정]소액공모공시서류(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Small-Scale Public Offering Disclosure' (소액공모공시서류) filed by Pharmabcine (주식회사 파멥신). It details a third-party allocation capital increase (유상증자) involving the issuance of new shares. This type of filing is a regulatory requirement for companies raising capital below a certain threshold (1 billion KRW) in South Korea, which falls under the category of share issuance and capital changes.
2023-08-24 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) and a subsequent amendment (정정신고) for the company Pharmabcine. It details the issuance of new shares, changes to payment dates, and the rationale for the capital increase. This falls under the category of share issuance and capital changes.
2023-08-24 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서(유상증자결정) 정정신고' (Report on Material Matters - Amendment to Capital Increase Decision). It details specific changes to a previously announced capital increase (share issuance), including adjustments to the number of shares, issue price, and payment dates. This falls under the category of announcements regarding new share issues or capital structure changes.
2023-08-17 Korean
[기재정정]소액공모공시서류(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Small-Scale Public Offering Disclosure' (소액공모공시서류) filed by PharmAbcine. It details a capital increase through a third-party allocation of shares. This type of filing is specifically for offerings under 1 billion KRW, which exempts the company from filing a full securities registration statement under the Capital Markets Act. Since this document describes the issuance of new shares and capital changes, it falls under the 'Share Issue/Capital Change' category.
2023-08-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.